Multiple Myeloma
Conditions
Brief summary
Patients with Multiple Myeloma will undergo single timepoint Positron Emission Tomography imaging with intravenously injected C11 Methionine to detect viable lesions.
Interventions
DRUGC11 Methionine positron emission tomography
diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
Sponsors
Yingbing Wang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Multiple Myeloma with symptomatic bone or soft tissue disease * Eastern Cooperative Oncology Group status 0 to 2 * Life expectance \>= 12 weeks * Ability to understand and willingness to sign informed consent * Tissue sampling with genotype data planned within 3 months of C11 positron emission tomography (PET) imaging
Exclusion criteria
* Pregnant or breast feeding * Claustrophobic reactions and unable to lie still on a bed inside the PET scanner for 60 minutes * Research related radiation exposure exceeding 50 millisieverts
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantitative measure of C11 Methionine uptake | 12 months | Standardized uptake value (a semiquantitative, unit less measure of radioactivity normalized for injected activity and body weight) will be measured for individual C11 Methionine uptake abnormalities (defined as focally increased uptake higher than background levels in a similar tissue type). All abnormal uptake not in locations common for benign etiologies, such as fracture and degenerative change, will be measured. |
Countries
United States
Outcome results
None listed